BIOMERICA LAUNCHING PRIVATE LABEL OTC PREGNANCY TESTS

BIOMERICA LAUNCHING PRIVATE LABEL OTC PREGNANCY TESTS modeled after Warner-Lambert's e.p.t. home pregnancy test and Johnson & Johnson's Fact Plus. Newport Beach, California-based Biomerica plans to begin shipping Fortel Midstream, a knock-off of e.p.t., and Fortel Plus, designed after J&J's product, during the first half of 1994. Biomerica's two new tests were among a number of new entries into the OTC testing market announced at the Private Label Manufacturers Association's annual trade show in Chicago Nov. 14- 17. Other private label versions of over-the-counter pregnancy tests launched at the trade show included Clinical Diagnostics, Inc.'s Sure Check and Qualis' Bio-Sentry one-step pregnancy tests. Biomerica's Fortel Midstream is comprised of a test stick and a desiccant (drying agent) and requires no urine collection, Biomerica said. The test stick features two viewing windows -- a control window that shows whether the test is working properly and a larger test window that shows the results of the test. On the other side of the test stick from the viewing windows are two absorbent windows through which a consumer urinates to begin the test; the stick must be held in the urine stream for at least six seconds to function properly. At five minutes, a result can be read in the viewing windows -- a rose/pink color band will appear in the test window if the result is positive; the absence of a color band indicates a negative result. Fortel Plus contains a test device, a urine dropper and a moisture-absorbent packet. Consumers are directed to collect urine in a cup, fill the dropper with urine and deposit six drops of urine into a well on the test device. After five minutes, a color band appears in a control window to indicate that the test has been completed; the test is invalid if the color band does not appear. As with the Fortel Midstream, the presence of a color band in the test window indicates a positive result, while the absence of a color band signifies a negative result. Biomerica estimated Fortel Midstream will carry a retail price of $8.99 while Fortel Plus will be priced around $6.99. According to Biomerica, e.p.t. and Fact Plus tests are retail priced at $12.99 and $13.99, respectively. Biomerica primarily manufactures and markets in vitro diagnostics for the physician's office and clinical laboratory markets. The company entered the OTC test market in 1991 with EZ Detect tests for hidden blood in the stool and urine. Chester, South Carolina-based Clinical Diagnostics' Sure Check one-step pregnancy test is copied from J&J's Fact Plus. Clinical Diagnostics expects to make the product available both under the Sure Check control name as well as to private label customers. Qualis' Bio-Sentry one-step home pregnancy test is expected to begin shipping to retailers in the beginning of January. In addition to being offered under the Bio-Sentry name, the test will be available to private-label customers including several "major chains," the company said. The Bio-Sentry test also is modeled after J&J's Fact Plus home pregnancy test. The OTC pregnancy test is Qualis' first foray into the home diagnostics market. The Des Moines-based company mostly manufactures personal care and dermatological OTCs, particularly focusing on "niche" products such as lice treatment items, medicated powders and antiseptic skin cleansers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Edwards Lifesciences Lowers Tariff Impact Forecast, Keeps Gross Margin Guidance Intact

 
• By 

The company reaffirmed its guidance for adjusted gross profit margin for the full year 2025 to remain within the original range of 78% to 79%. Chief financial officer Scott Ullem attributed this to currency and tariff dynamics.

Olympus, Revival Co-Found Swan In $458M Deal, Face Tech and Regulatory Hurdles

 
• By 

Olympus and Revival Healthcare Capital have launched Swan Endosurgical in a $458m milestone-based joint venture to develop a robotic platform for endoluminal surgery. The deal combines Olympus’ GI expertise with Revival’s start-up model, but will face technical and regulatory hurdles.

Alternative Funding Sources Emerge Amid Biotech Industry Challenges

 
• By 

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.